The FDA announced that it has approved rifamycin for the treatment of travelers’ diarrhea caused by noninvasive Escherichia coli strains in adults.
Travelers’ diarrhea affects approximately 10% to 40% of travelers worldwide each year, making it the most common travel-related illness, according to the FDA. People traveling to areas in Asia, the Middle East, Africa, Mexico and Central and South America have the greatest risk for contracting the disease.
This activity is supported by an educational grant from ViiV Healthcare.
Zika Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.